NCT01909934_exc_text
exclusion
Previous treatment with brentuximab vedotin.
Previously received an allogeneic transplant.
Patients with current diagnosis of primary cutaneous ALCL (patients whose ALCL has transformed to sALCL are eligible).
Known cerebral/meningeal disease including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
Female patients who are lactating and breastfeeding or pregnant
Known human immunodeficiency virus (HIV) positive
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection

NCT01909934_exc_T1
Drug
brentuximab
NCT01909934_exc_T2
Procedure
allogeneic transplant
NCT01909934_exc_T3
Condition
primary cutaneous ALCL
NCT01909934_exc_T4
Condition
sALCL
NCT01909934_exc_T5
Condition
meningeal disease
NCT01909934_exc_T6
Condition
ebral/me ease in
NCT01909934_exc_T7
Condition
progressive multifocal leukoencephalopathy
NCT01909934_exc_T8
Condition
PML
NCT01909934_exc_T9
Scope
cerebral/meningeal disease
NCT01909934_exc_T11
Measurement
human immunodeficiency virus
NCT01909934_exc_T12
Measurement
HIV
NCT01909934_exc_T13
Value
positive
NCT01909934_exc_T14
Measurement
hepatitis B surface antigen
NCT01909934_exc_T15
Value
positive
NCT01909934_exc_T16
Condition
hepatitis C infection
NCT01909934_exc_T17
Qualifier
active